Evidence map›Paper›PMID 25584888›Full record

ArticleCancer cell2015

Breaking up is hard to do: PI3K isoforms on the rebound.

David W Cescon, Chiara Gorrini, Tak W Mak

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. PI3K: A Crucial Piece in the RAS Signaling Puzzle.Cold Spring Harbor perspectives in medicine · 2018
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David W CesconCampbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre/University Health Network, Toronto, ON M5T 2M9, Canada; Medical Oncology and Hematology, Princess Margaret Cancer Centre/University Health Network and University of Toronto, ON M5T 2M9, Canada.
Chiara GorriniCampbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre/University Health Network, Toronto, ON M5T 2M9, Canada.
Tak W MakCampbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre/University Health Network, Toronto, ON M5T 2M9, Canada. Electronic address: tmak@uhnresearch.ca.
Princess Margaret Cancer Centre · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Cancer Cell, Schwartz and colleagues and Costa and colleagues demonstrate that inhibition of PI3Kα or PI3Kβ in cancer cells with hyperactivated PI3Kα or PI3Kβ, respectively, activates the other isoform, leading to a "rebound" of the PI3K activity through different compensation mechanisms.

Indexed as

Phosphoinositide-3 Kinase InhibitorsAniline CompoundsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChromonesClass I Phosphatidylinositol 3-KinasesFemaleHumansNeoplasmsortho-AminobenzoatesProtein Kinase InhibitorsPTEN PhosphohydrolasePyrimidinonesThiazoles2-(1-(7-methyl-2-morpholin-4-yl-4-oxo-4H-pyrido(1,2-a)pyrimidin-9-yl)ethylamino)benzoic acidAlpelisibAniline CompoundsAZD8186ChromonesClass I Phosphatidylinositol 3-Kinasesortho-AminobenzoatesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsPTEN PhosphohydrolasePyrimidinonesThiazoles

Identifiers

PMID25584888
OpenAlexW1996500502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.